New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
06:30 EDTVRXValeant reports Q2 GAAP EPS 37c, Q2 cash EPS $1.91
Reports Q2 revenue $2B, up 86% from a year ago driven by strong growth in almost all of our businesses. Reports Europe SSS organic growth of 13%, Asia SSS organic growth of 17%, US contact lens business organic growth of 37% and US Bausch+Lomb consumer business organic growth of 12%.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use